troglitazone has been researched along with Fistula in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Fistula: Abnormal communication most commonly seen between two internal organs, or between an internal organ and the surface of the body.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, H | 1 |
| Sato, Y | 1 |
| Kanai, S | 1 |
| Ichikawa, M | 1 |
| Funakoshi, A | 1 |
| Miyasaka, K | 1 |
1 other study available for troglitazone and Fistula
| Article | Year |
|---|---|
Increased lymphatic lipid transport in genetically diabetic obese rats.
Topics: Animals; Bile Acids and Salts; Body Weight; Carrier Proteins; Chromans; Diabetes Mellitus; Diabetes | 2002 |